Zai Lab Limited (HKG:9688)
27.60
-1.10 (-3.83%)
Jun 27, 2025, 4:08 PM HKT
Zai Lab Revenue
Zai Lab had revenue of $106.49M USD in the quarter ending March 31, 2025, with 22.19% growth. This brings the company's revenue in the last twelve months to $418.33M, up 43.72% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$418.33M
Revenue Growth
+43.72%
P/S Ratio
9.66
Revenue / Employee
$223.82K
Employees
1,869
Market Cap
31.45B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 32.49B |
Hansoh Pharmaceutical Group Company | 13.05B |
Innovent Biologics | 10.03B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
Sino Biopharmaceutical | 30.72B |
CSPC Pharmaceutical Group | 28.99B |
Akeso | 2.26B |
Zai Lab News
- 14 days ago - Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 - Business Wire
- 25 days ago - NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Benzinga
- 25 days ago - Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Business Wire
- 27 days ago - Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire
- 4 weeks ago - Zai Lab Announces Participation in Investor Conferences in June 2025 - Business Wire
- 4 weeks ago - Zai Lab Limited Is Well Positioned For Long-Term Growth - Seeking Alpha
- 5 weeks ago - Zai Lab Limited: Banking On Chinese Pharma Growth - Seeking Alpha
- 5 weeks ago - Zai Lab gets FDA fast track status for lung cancer treatment - Seeking Alpha